doramapimod

Doramapimod is a small molecule inhibitor of p38 mitogen-activated protein kinase (MAPK), specifically targeting the α, β, and γ isoforms. It acts as an immunomodulator by inhibiting the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNFα) and interleukin 1 beta (IL‑1β). Doramapimod has been investigated for its anti-inflammatory effects in diseases like rheumatoid arthritis, Crohn's disease, and psoriasis. Its main mechanism involves blocking p38 MAPK activity, thereby reducing inflammatory signaling pathways. The drug was initially developed by Boehringer Ingelheim and reached up to Phase 2/3 clinical trials for several autoimmune indications but did not progress to approval[1][2][4][5][6].

Other names

doramapimod